Nexalin Technology (NASDAQ:NXL – Get Free Report) is one of 76 public companies in the “Electromedical equipment” industry, but how does it weigh in compared to its rivals? We will compare Nexalin Technology to related companies based on the strength of its earnings, risk, valuation, analyst recommendations, institutional ownership, profitability and dividends.
Risk and Volatility
Nexalin Technology has a beta of 5.53, meaning that its share price is 453% more volatile than the S&P 500. Comparatively, Nexalin Technology’s rivals have a beta of 12.70, meaning that their average share price is 1,170% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings and price targets for Nexalin Technology and its rivals, as provided by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Nexalin Technology | 0 | 0 | 0 | 0 | N/A |
Nexalin Technology Competitors | 252 | 769 | 2038 | 101 | 2.63 |
Earnings & Valuation
This table compares Nexalin Technology and its rivals top-line revenue, earnings per share and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Nexalin Technology | $110,000.00 | -$4.65 million | -2.52 |
Nexalin Technology Competitors | $986.96 million | $82.19 million | -8.53 |
Nexalin Technology’s rivals have higher revenue and earnings than Nexalin Technology. Nexalin Technology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
0.7% of Nexalin Technology shares are held by institutional investors. Comparatively, 45.1% of shares of all “Electromedical equipment” companies are held by institutional investors. 27.7% of Nexalin Technology shares are held by insiders. Comparatively, 14.8% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Nexalin Technology and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Nexalin Technology | -3,088.12% | -154.84% | -122.94% |
Nexalin Technology Competitors | -152.14% | -47.46% | -5.34% |
Summary
Nexalin Technology rivals beat Nexalin Technology on 8 of the 10 factors compared.
Nexalin Technology Company Profile
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.